Background
Preeclampsia is an important cause of maternal and perinatal morbidity and mortality, affecting 2–8% of pregnancies worldwide.
Aim
The study aimed to examine the potential value of maternal serum concentration of placental protein 13 (PP13) in early diagnosis of preeclampsia (11–13 weeks of gestation).
Patients and methods
This study was carried out on 120 pregnant women at risk for preeclampsia (60 women with advanced maternal age >35 years, and 60 women with a history of chronic hypertension, diabetes, kidney disease, and systemic lupus erythematosus) and 40 women apparently healthy as controls. Serum PP13 was measured by the enzyme-linked immunosorbent assay kits from SinoGeneClon Biotech Co. Ltd, catalog number: SG-10912. Patients signed an informed consent form. Assiut Faculty of Medicine approved The study was approved by the Ethical Committee of Faculty of Medicine Assiut University, with registration number IRB: 17101046.
Results
PP13 was significantly decreased in pregnant women with risk factors for preeclampsia (women with advanced maternal age > 35 years, as well as women with a history of chronic hypertension, diabetes, kidney disease, and systemic lupus erythematosus) compared with the control group.
Conclusion
This study has revealed that serum levels of PP13 can be used as a predictive test in preeclampsia.